In a groundbreaking study published in Cell Death Discovery, researchers have unveiled a novel molecular pathway by which Fibroblast Growth Factor Receptor 1 (FGFR1) curtails ovarian cancer progression. This discovery illuminates the intricate metabolic reprogramming governed by FGFR1 through its modulation of SIRT3-dependent lactylation, a post-translational modification that is gaining recognition for its role in cancer biology. The study represents a significant leap forward in understanding the metabolic underpinnings that drive ovarian tumorigenesis and offers fresh avenues for therapeutic intervention.
Ovarian cancer remains a formidable challenge in oncology, often diagnosed at an advanced stage due to subtle symptomatology and limited early detection methods. The tumor microenvironment’s metabolic landscape is pivotal in sustaining cancer cell proliferation, survival, and metastasis. Here, FGFR1, a receptor tyrosine kinase, emerges as a potent suppressor whose signaling appears to reprogram metabolic pathways crucial for ovarian cancer cell growth. The research team, led by Jiang, Huang, and Dong, meticulously dissected how FGFR1 orchestrates this metabolic shift through the delicate regulation of SIRT3, a mitochondrial deacetylase previously implicated in cellular metabolism and oxidative stress response.
Central to the study is the identification of lactylation, a relatively new post-translational modification deriving from lactate, as a critical biochemical event modulated by FGFR1. Lactylation modifies lysine residues on histones and other proteins, thereby influencing gene expression and cellular functions. By leveraging cutting-edge proteomics and metabolomics analyses, the researchers demonstrated that FGFR1 signaling downregulates lactylation levels via SIRT3 activation. This modulation hampers the cancer cells’ ability to exploit glycolytic metabolism—a hallmark of many aggressive tumors—thereby impairing their proliferative capacity and malignancy.
This FGFR1-SIRT3-lactylation axis represents a hitherto unrecognized metabolic checkpoint in ovarian cancer. Importantly, the study elucidated that FGFR1 activation enhances SIRT3 deacetylase activity, which in turn reduces protein lactylation and shifts the metabolic balance away from aerobic glycolysis toward oxidative phosphorylation. This metabolic rewiring deprives cancer cells of the bioenergetic and biosynthetic resources essential for rapid growth and invasion. The findings compellingly position FGFR1 not just as a receptor involved in growth factor signaling but as a master regulator of cancer cell metabolism through epigenetic and enzymatic modifications.
Mechanistically, this work underscores the dual role of SIRT3 both as a mediator of mitochondrial function and as a modulator of histone lactylation status, thereby linking metabolic shifts to epigenetic regulation. The researchers used sophisticated in vitro and in vivo ovarian cancer models to validate their findings. Knockdown and overexpression experiments revealed that loss of FGFR1 signaling heightened lactylation, enhanced glycolytic flux, and promoted tumor growth, while reinstatement of FGFR1 curtailed these oncogenic processes. These functional studies highlight the therapeutic potential of restoring or mimicking FGFR1 activity to subvert ovarian cancer progression.
The implications of this discovery extend beyond ovarian cancer. Since metabolic reprogramming is a universal feature of many malignancies, targeting the FGFR1-SIRT3-lactylation pathway could have broad applications across diverse tumor types. Traditionally, FGFR1 has been studied for its proliferative and survival signaling roles in cancer; however, this study shifts the paradigm by demonstrating its tumor-suppressive function via metabolic modulation. This nuanced understanding challenges current approaches and encourages the design of novel therapeutic strategies that exploit metabolic vulnerabilities in cancer cells.
One of the exciting aspects of this research is its contribution to the burgeoning field of lactylation biology. Since lactylation was only recently characterized, its impact on cancer remained elusive. By linking lactylation dynamics to FGFR1 and SIRT3, the study provides concrete evidence that lactate-derived modifications are integral to controlling cancer metabolism and epigenetics. This insight could fuel further investigations into lactylation-targeted therapies, perhaps involving small molecules or peptides designed to modulate lactylation enzymes directly.
From a clinical perspective, the findings advocate for integrating FGFR1 status and metabolic profiling into ovarian cancer diagnostics and treatment planning. Biomarkers reflective of lactylation levels or SIRT3 activity might enable patient stratification and prognostication. Moreover, therapeutic agents that activate FGFR1 or enhance SIRT3 function could be developed and combined with existing chemotherapies to achieve synergistic antitumor effects. Given the notorious chemoresistance and relapse rates in ovarian cancer, metabolic intervention strategies could significantly improve patient outcomes.
Importantly, the study highlighted the robust interplay between metabolic enzymes and epigenetic modifications in cancer cells. By showing that metabolic enzymes like SIRT3 act beyond their canonical roles to influence histone modification landscapes, it bridges two major realms of cancer research—metabolism and epigenetics. This cross-disciplinary nexus is likely to spur more integrated studies aimed at unraveling how metabolic states remodel the chromatin environment to alter gene expression programs favoring tumor survival and dissemination.
The researchers utilized state-of-the-art CRISPR-Cas9 gene editing, stable isotope tracing, and high-resolution mass spectrometry to map the biochemical pathways involved. These technical advancements allowed for a comprehensive characterization of metabolic fluxes and post-translational modifications, lending robustness and precision to their conclusions. Their integrative approach sets a new standard for dissecting complex signaling-metabolic networks in cancer and exemplifies the power of multi-omic strategies.
Future research inspired by this study may focus on delineating how FGFR1 signaling is regulated in the tumor microenvironment and whether its metabolic regulatory functions are conserved in other cancer subtypes. Furthermore, exploring the crosstalk between lactylation and other epigenetic modifications could reveal hierarchical regulatory mechanisms that govern tumor metabolism and chromatin remodeling. Deciphering these layers of regulation will be crucial for identifying pivotal intervention points susceptible to pharmacologic manipulation.
This seminal work also raises important questions regarding the metabolic plasticity of cancer cells and their ability to adapt to therapeutic pressures. Since metabolic reprogramming is reversible and context-dependent, understanding how FGFR1 and SIRT3 influence this adaptability could inform strategies to prevent or overcome resistance phenomena. Targeting metabolic checkpoints such as lactylation represents an innovative route to undermine cancer cell survival strategies in a dynamic tumor ecosystem.
In summary, the study by Jiang, Huang, Dong, and colleagues represents a landmark contribution to cancer biology, elucidating a novel FGFR1-SIRT3-mediated mechanism that suppresses ovarian cancer progression by regulating lactylation and metabolic pathways. Their insights not only deepen our understanding of tumor metabolism but also open new therapeutic possibilities that could transform the management of ovarian cancer and potentially other malignancies. As research continues to unravel the complexity of cancer metabolism and epigenetics, the FGFR1-SIRT3-lactylation axis stands out as a promising molecular target demanding further exploration and clinical translation.
Subject of Research: Ovarian cancer progression and metabolic reprogramming mediated by FGFR1 and SIRT3-dependent lactylation
Article Title: FGFR1 suppresses ovarian cancer progression by modulating SIRT3-dependent lactylation and metabolic reprogramming
Article References:
Jiang, F., Huang, H., Dong, Z. et al. FGFR1 suppresses ovarian cancer progression by modulating SIRT3-dependent lactylation and metabolic reprogramming. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03054-6
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41420-026-03054-6
Tags: FGFR1 ovarian cancer suppressionFGFR1 signaling pathwayslactylation role in cancer biologymetabolic reprogramming in cancermetabolic shifts in cancer cellsmitochondrial metabolism in tumorigenesisovarian tumor microenvironment metabolismpost-translational modifications in oncologyreceptor tyrosine kinase cancer regulationSIRT3 mitochondrial deacetylase functionSIRT3-dependent lactylationtherapeutic targets in ovarian cancer
